



Economic Self-Determination and Commercialization of Subsistence Marine Resources of Alaska Natives

*8th Meeting of the UN Open-ended Informal Consultative Process
on Oceans and the Law of the Sea*

May 26, 2007

*Maureen A. McKenzie, Ph.D.
Chief Executive Officer
DENALI BioTechnologies, LLC
Soldotna, Alaska*

Alaska Marine and Forest Products

- Modern utilization for commercial purposes based principally on the enduring wisdom of Alaska Natives
 - Subsistence foods and traditional medicines
- In local industries these products typically marketed as:
 - Specialty wild food/menu items, jams/jellies, and confections
 - Teas and health-oriented beverage ingredients
 - Hand-crafted medicinals and tonics
 - Boutique cosmetics and personal care products
 - Home environment enhancing products
- Beyond established commercial fisheries, new opportunity must derive from *sustainable* resources and supply chains for emerging large, high-value markets

DENALI
BioTechnologies



Denali's Vision

- Develop Alaska's exceptional wilderness and marine bioresources for high-quality:
 - Nutraceuticals
 - Cosmeceuticals
 - Phytopharmaceuticals (Herbals)
 - Pharmaceuticals
- Promote bioresources with plentiful *bona fide* "bioactives" for improving health and quality of life
- Create sustainable economic development from renewable resources, notably in underdeveloped rural areas, through environmentally-friendly processes

DENALI
BioTechnologies



Nutraceutical Industry Statistics

- Tremendous untapped opportunities exist for in large markets
- Revenues from nutraceuticals
 - >\$75BB by 2007 in U.S.
 - >\$210BB globally, growing to >\$310BB by 2010
 - Adjusted annual growth rate of:
 - +9% for botanicals
 - +18% for fortified beverages
 - +22% for natural foods
 - +27% for functional food
- Compare to ~\$55 BB annual research commitment by major U.S. pharmaceutical companies

DENALI
BioTechnologies

Biodiversity Sources of Alaska

- Inherent biodiversity in 20 USGS ecoregions
 - 6+ climatic zones (12 with maritime features)
 - Every major geologic period represented
 - Pre-ice age, unglaciated tracts; 10,000 extant glaciers
 - 89 volcanoes with hotsprings and boiling mudpots



- Enormous metal and mineral deposits
- 2 old-growth rainforest stands (33 MM acres)
- 5 tundra types and bogs
- Sea level to 20,300 feet
- 33,000 miles of coastline

DENALI
BioTechnologies





Alaska's Unique Environment

- Vast Alaska wilderness and marine environments provide rich sources of novel commercial products
- Result from extreme environmental stresses
 - Unusual species and novel molecules emerge through biochemical/genetic adaptation to harsh conditions
- Biotic
 - Herbivory (mammals, birds, insects), microbial pathogens
- Abiotic
 - Photoperiod length / UV exposure (60 days to 200 days)
 - Nutrient-poor soils, high levels of metals (e.g. arsenic)
 - Precipitation (150mm to 2500mm; 6 in. to 150 in.)
 - Temperature (-63°C to 35°C; -82°F to 95°F)
 - **Most organisms are psychrophilic or cold-adapted**


DENALI
BioTechnologies

Discovery Strategies

- **Random Bioprospecting**
 - Small quantities of soils, sediments, coastline samples
 - Cultivable microbes and nucleic acid recovery from uncultivable organisms that yield enzymes/biocatalysts
 - Exclusively for pharmaceutical discovery
- **Targeted Bioprospecting**
 - Focused collections of small amounts of plants, soils, sediments, etc. directed by chemotaxonomy, chemical ecology (abiotic/biotic stress), extreme conditions
 - Principally for pharmaceutical discovery or cosmeceuticals
- **Ethnopharmacology**
 - Alaska Native traditional medicine and subsistence diets offer hundreds of plant, fungal, animal, and marine candidates for product R&D

DENALI
BioTechnologies

Maximum Fieldwork Output




DENALI
BioTechnologies

Discovery Strategies

- Random Bioprospecting
 - Small quantities of soils and sediments
 - Cultivable microbes and nucleic acid recovery from uncultivable organisms that yield enzymes/biocatalysts for pharmaceutical discovery
- Targeted Bioprospecting
 - Focused collections of small amounts of plants, soils, sediments, etc. directed by chemotaxonomy, chemical ecology (abiotic/biotic stress), extreme conditions
 - Principally for pharmaceutical discovery or cosmeceuticals
- Ethnopharmacology
 - Alaska Native traditional medicine and subsistence diets offer hundreds of plant, fungal, animal, and marine candidates for product R&D



DENALI
BioTechnologies





Alaska Native Claims Settlement Act

- Alaska Natives extinguished sovereign rights to land and resources for \$962.5 million in 1971
- ANCSA prevented formation of reservations after Alaska statehood was granted in 1959
 - One reservation formed voluntarily (Metlakatla) and one tribal government / reserve (Venetie)
- ~10% of Alaska land belongs to ANCSA entities
 - 13 Regional Corporations – subsurface rights
 - 200+ Village Corporations – surface / coastal access rights
 - Tribal councils advise on cultural issues; no economic status
 - Contrast to ~65% Federal, ~25% State, <1% private lands
- Intended to provide for economic self-determination

DENALI
BioTechnologies



Bioprospecting Model

- Research and commercial development activities require access for bioprospecting of marine resources and non-timber forest products
- Legal considerations involving ownership and compensation to government or landholder
 - Collaborating landholders are primarily Alaska Native corporations / tribal councils
 - Federal and State landholders governed by law
- Denali (and predecessor companies) crafted the pioneering “Biodiversity Access Agreement” for Alaska – self-imposed code of ethics
 - Based on common sense and “Golden Rule”

DENALI
BioTechnologies



“Fair Treatment ” Agreement

- Denali’s version of the “Fair Trade” Agreement
 - New initiative introduced for consideration in May, 2007
 - Targeted to accommodate diverse needs and expectations of Alaska Native organizations
 - Engage Federal and State agencies / landholders in active management beyond established protection laws – **for responsible commercialization** – of biodiversity and high-value marine bounty and non-timber forest products
- Fundamental objectives:
 - Establish uniform system of access/utilization rights
 - Determine fair compensation for harvest
 - Critical for ability of corporate partners to compete in marketplace and generate revenues and economic development

DENALI
BioTechnologies



“Fair Treatment ” Agreement

- More advanced considerations include:
 - Prioritization of rural villages in most critical need of economic opportunities for resource commercialization
 - Many have >70% unemployment, are on the brink of total bankruptcy, have no infrastructure including running water or sewer facilities, no clinics/dental services, etc.
- Most advanced considerations include intellectual property (IP) rights of Alaska Natives
- Denali created a means to convert side-by-side orally passed knowledge into scientific methodologies
 - No disclosure of spiritual or culturally sensitive information
- Transform standard pharma/biotech industry royalty into more value for traditional knowledge

DENALI
BioTechnologies



“Fair Treatment” Agreement

- Compensation criteria:
 - “Passive” access to land
 - Royalty on profits from commercialized product (0.5 - 2%)
 - “Guided” access to land
 - Profit-sharing (negotiated, up to 10%)
 - “Contributing” access to land and knowledge
 - Profit-sharing and patent rights (negotiated, up to 50%)
- Incentives for responsible corporate partners who:
 - Pay appropriate prices for raw products
 - Local processing to add value in the State of Alaska
 - Create rural/local employment
 - Contribute financial support to determine/establish sustainability of resources and minimize footprint
 - Conduct/share research to identify valuable new resources

DENALI
BioTechnologies



Lessons from Alaska Natives

- Before “Western” acculturation, very low prevalence of cardiovascular disease, diabetes and cancer
- Most valuable for studies of “Nature vs. Nurture”
 - Cultures date to >15,000 YA
 - Role of diet in health/disease
 - Medicinal foods are staples in traditional Alaska Native diets
- Traditional medicine is practiced and viable
 - Untapped information for pharmaceutical discovery
- Impetus for developing flagship products
 - Abundant wild berries and rosehips
 - Future dietary supplements from other abundant subsistence foods, including fish (salmon), kelp, etc.

DENALI
BioTechnologies



Fish-Derived Product Line

- Functional food ingredients from pink salmon
 - Market collapsed for canned product
 - Hatcheries throughout Alaska yield millions of unconsumed fish and rural streams are chock full while villagers “starve”
 - New market for RWD product with mild flavor and high essential nutrient content (i.e. omega-3 fatty acids)
 - Particular value for infant formula/food, enteral formulations, etc.
- “Waste” flesh and racks for calcium supplement
 - Natural bone provides Ca⁺⁺, Mg⁺⁺ and trace minerals along with Vitamin D, omega-3 fatty acids, and astaxanthin
 - Utilize millions of pounds of biomass instead of dumping
- Discarded roe is excellent source of nutrients
- Skin/scales used in cosmetics

DENALI
BioTechnologies



Side View of Refractance Window® Drier (RWD)

DENALI
BioTechnologies



Dried Salmon Roe Flakes Exiting Drier Belt

DENALI
BioTechnologies

Marine Mammal PUFA Project

- Key observations and drivers:
 - Alaska Natives who consume high quantities of marine mammal fat (coastal populations) do not suffer from high rates of central nervous system (CNS) disease or depression
 - Interior populations tend to be more prone to depression
- To find the reason, seal oil prepared in a traditional manner as food is under analysis for novel essential polyunsaturated fatty acids (PUFA)
 - Many novel PUFA in addition to EPA and DHA
 - Compare / contrast to common salmon PUFA
- Enzymatically convert common salmon PUFA to novel seal PUFA, separate, and screen for CNS effects

DENALI
BioTechnologies

Future Challenges

- Sustainability of marine and non-timber resources
 - Identify those appropriate for desired market
 - Nutraceuticals demand abundant resources and harvest volume
 - Cosmeceuticals consume far less resources (~10% of above)
 - Pharmaceuticals require very limited harvest and footprint
- Protect high intrinsic resource value during processing
- Supply chains
 - Determine fair prices for harvest
 - Critical for ability to compete in marketplace
 - Develop efficient logistical, transport and storage strategies
 - Minimize spoilage/waste and control shipping costs
- Establish priority villages for commercial partnerships

DENALI
BioTechnologies

Contact Information

Maureen A. McKenzie, Ph.D.
Chief Executive Officer

Gordon S. Haines
President

35555 Spur Highway
PMB 321

Soldotna, Alaska 99669
907.283.5000

www.denali-biotechnologies.com



DENALI
BioTechnologies